Reminder: Invitation to Roche ’s virtual Neuroscience Update IR Event

  We are pleased to invite investors and analysts to participate in our virtual event onMonday,30 October2023, highlighting Roche ’s Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator). 17:00 – 18:15 CET / 16:00 - 17:15GMT12:00 – 1:15 pm EDT / 9:00 – 10:15 am PDT  The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 16:00 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor RelationsNeuroscience Strategy UpdatePaulo Fontoura, SVP and Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical DevelopmentMS - ECTRIMS data reviewStephen L. Hauser, Director, UCSF Weill Institute of NeurosciencesAD - CTAD data reviewLuka Kulic, Therapeutic Area Leader Dementias, Medical Director Neuroscience and Rare DiseasesQ&A Access to virtual event (pre-registration required)Please pre-register for our webinarhere*.  Should you be unable to register for the webinar due to your company IT policy, please send an e-mail [e-mail].  A replay of the webcast will be available via>ir.roche.com *privacy notice  Best regards,  Bruno EschliHead of Investor Relations   Roche Investor Relations Dr. Bruno EschliPhone: [phone]e-mail:[e-mail] Dr. Sabine Borngr äberPho...

Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news